Contingency Management for Attendance - 2

This study has been completed.
Sponsor:
Collaborator:
University of Connecticut Health Center
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00249639
First received: November 3, 2005
Last updated: May 23, 2008
Last verified: May 2008
  Purpose

The purpose of this study is to evaluate the effectiveness of a low-cost contingency management procedure as compared to standard treatment. Using a cross-over design, CM is implemented at different community-based clinics and compared with non-CM in the same facilities. Research staff collects information regarding patients' demographic characteristics, attendance, and outcomes at the clinics. During Phase A (non-CM), standard clinical practice is in place. During Phase B (CM), all patients have the chance to win prizes by coming to treatment. Each participating clinic is randomly assigned to receive either the A or B phase first; each phase is in effect for 16 weeks.


Condition Intervention
Substance Abuse
Behavioral: Contingency management

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Contingency Management for Attendance

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use [ Time Frame: baseline and each follow-up ] [ Designated as safety issue: No ]
  • Retention [ Time Frame: baseline and each follow-up ] [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: January 2004
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Contingency management
    Rewards valued $1-$100
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Subjects will be patients in treatment at one of the participating clinics during the study period. There are no other inclusion or exclusion criteria because we wish to make enrollment open to increase generalizability.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249639

Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
University of Connecticut Health Center
Investigators
Principal Investigator: Nancy Petry, Ph.D. University of Connecticut Health Center
  More Information

No publications provided

Responsible Party: Nancy Petry, Ph.D., UConn Health Center
ClinicalTrials.gov Identifier: NCT00249639     History of Changes
Other Study ID Numbers: NIDA-16855-2, R01-16855-2
Study First Received: November 3, 2005
Last Updated: May 23, 2008
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by National Institute on Drug Abuse (NIDA):
Contingency Management
Substance Abuse Treatment

ClinicalTrials.gov processed this record on September 30, 2014